scholarly journals Sodium Sensitivity of Blood Pressure Appearing Before Hypertension and Related to Histological Damage in Immunoglobulin A Nephropathy

Hypertension ◽  
2001 ◽  
Vol 38 (1) ◽  
pp. 81-85 ◽  
Author(s):  
Yoshio Konishi ◽  
Noriyuki Okada ◽  
Mikio Okamura ◽  
Takashi Morikawa ◽  
Michiaki Okumura ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Immunoglobulin A ◽  
Immunoglobulin A Nephropathy ◽  
Sodium Sensitivity ◽  
Histological Damage

Aggregation of erythrocyte sodium/lithium countertransport activity in families of patients with immunoglobulin A nephropathy

1992 ◽  
Vol 83 (2) ◽  
pp. 241-245 ◽  
Author(s):  
A. Fabbri ◽  
R. Boero ◽  
E. Degli Esposti ◽  
C. Guarena ◽  
A. Lucatello ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Iga Nephropathy ◽  
Poor Prognosis ◽  
Genetic Factors ◽  
Immunoglobulin A ◽  
Mean Blood Pressure ◽  
Immunoglobulin A Nephropathy ◽  
Normal Range ◽  
Erythrocyte Sodium

1. We evaluated the inheritance of erythrocyte Na+/Li+ countertransport activity in IgA nephropathy by assessing this parameter in 19 patients with biopsy-proven IgA nephropathy and in their 53 relatives (32 parents and 21 siblings). The possible use of erythrocyte Na+/Li+ countertransport activity as a marker of poor prognosis was also evaluated. 2. A significant correlation was found between ‘familial’ and proband Na+/Li+ countertransport activity, but not between that of spouses. 3. Mean blood pressure, although within the normal range, and Na+/Li+ countertransport activity were significantly higher in patients with proteinuria than in those without proteinuria. 4. Parents of proteinuric patients had a higher Na+/Li+ countertransport activity than parents of non-proteinuric patients. 5. In IgA nephropathy the inheritance of erythrocyte Na+/Li+ countertransport activity was preserved. Therefore genetic factors could play a role in the non-immunological progression of IgA nephropathy.

scholarly journals Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Lingzhi Wu ◽  
Di Liu ◽  
Ming Xia ◽  
Guochun Chen ◽  
Yu Liu ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Cox Regression ◽  
Immunoglobulin A ◽  
Study Endpoint ◽  
Immunoglobulin A Nephropathy ◽  
Renal Outcomes ◽  
Kaplan Meier ◽  
Renal Prognosis ◽  
The Impact

Abstract Background Immunoglobulin A nephropathy (IgAN) is identified as mesangial IgA deposition and is usually accompanied by other immunofluorescence deposits. The impact of immunofluorescent features in IgAN patients, however, remains unclear. Methods Baseline clinicopathologic parameters and renal outcomes of 337 patients diagnosed with IgAN between January 2009 and December 2015 were analyzed. We then categorized these patients into four groups: without immunofluorescence deposits, mesangial-only, mesangial and glomerular capillary loops (GCLs), and GCLs-only. The study endpoint was end-stage kidney disease (ESKD) or a ≥ 50% decline in the estimated glomerular filtration rate (eGFR). Kaplan–Meier and Cox regression analyses were performed to calculate renal survival. Results Of the 337 IgAN patients, women comprised 57.0%. Compared to patients with IgA deposition in the mesangial-only group, patients with IgA deposition in the mesangial +GCLs group were much heavier, and exhibited higher systolic blood pressure, lower serum IgG levels, and heavier proteinuria (all P < 0.05). Patients with IgG deposition in the mesangial +GCLs group presented with higher levels of cholesterol, heavier proteinuria than IgG deposition in the mesangial-only group (both P < 0.05). Compared with the mesangial-only group exhibiting C3 deposits, patients in the mesangial +GCLs group with C3 deposition had a higher systolic blood pressure (P = 0.028). A total of 38 patients (11.3%) continued to the study endpoint after a median follow-up time of 63.5 months (range,49.8–81.4). Kaplan–Meier analysis and Cox regression analysis showed that C1q deposition in the mesangial +GCLs group predicted a poor renal prognosis. Conclusions IgA and IgG deposits in the mesangial region and GCLs were associated with more unfavorable clinical and histopathologic findings in IgAN patients. C1q deposition in the mesangial region and GCLs predicted a poor renal prognosis. However, the impact of the pattern of immunofluorescence deposits on renal outcomes remains to be proven by further investigation.

Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation

Nephrology ◽  
2013 ◽  
Vol 18 (12) ◽  
pp. 808-812 ◽  
Author(s):  
Kiyohiko Hotta ◽  
Yuichiro Fukasawa ◽  
Mayuko Akimoto ◽  
Tatsu Tanabe ◽  
Hajime Sasaki ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Immunoglobulin A ◽  
Immunoglobulin A Nephropathy ◽  
Histological Damage

Treatment of IgA Nephropathy: An Update

2011 ◽  
Vol 45 (10) ◽  
pp. 1284-1296 ◽  
Author(s):  
Jennifer L Rosselli ◽  
Stacey M Thacker ◽  
Julie P Karpinski ◽  
Katherine A Petkewicz
Keyword(s):  
Blood Pressure ◽  
Iga Nephropathy ◽  
Treatment Options ◽  
Immunoglobulin A ◽  
Omega 3 ◽  
Immunoglobulin A Nephropathy ◽  
Angiotensin Ii Receptor ◽  
Urine Protein ◽  
Converting Enzyme Inhibitors ◽  
Medline Search

Objective: To review current literature regarding treatment options for immunoglobulin A nephropathy (IgAN). Data Sources: A MEDLINE search was performed using the terms IgA nephropathy, Berger's disease, immunoglobulin A nephropathy, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, fish oil, omega-3 fatty acids, statins. hydroxymethylglutaryl-CoA reductase Inhibitors, immunosuppressive therapy, corticosteroids, mycophenolate mofetil, cyclophosphamide, cyclosporine, azathioprine, leflunomide, antiplatelets, anticoagulants, vitamin E, infliximab, calcitriol, and intravenous immunoglobulins. A date limit was not set; however, focus was on publications from 1999 to June 2011 to review recent literature and therapeutic recommendations. Study Selection and Data Extraction: All articles in English, including studies conducted in humans, meta-analyses, review articles, guidelines, statements, and reference citations, were identified and evaluated. Data Synthesis: IgAN is the most common primary glomerulonephritis worldwide, leading to end-stage renal disease in 20–30% of patients. Evidence guiding management of IgAN has been sparse and clinical trials have not conclusively demonstrated effective treatments, largely due to suboptimal methodologies. Treatment strategies have included management of blood pressure and lipids, improvement or stabilization of kidney function, and reduction of proteinuria. This review of IgAN provides an update regarding standard and nonconventional treatment options based on recently published literature. Conclusions: Supportive therapies, including angiotensin blockade, should be considered as first-line therapy for patients with urine protein >0.5 g/day and/or blood pressure > 140/90 mmHg, Corticosteroids could be considered as add-on or monotherapy for patients with urine protein >1 g/day with preserved renal function. Conclusive data are lacking for general treatment recommendations for the use of other therapies for IgAN.

scholarly journals Role of Genetic Polymorphism in the SA Gene on the Blood Pressure and Prognosis of Renal Function in Patients with Immunoglobulin A Nephropathy.

2002 ◽  
Vol 25 (6) ◽  
pp. 831-836 ◽  
Author(s):  
Ichiei NARITA ◽  
Noriko SAITO ◽  
Shin GOTO ◽  
Arimasa SHIRASAKI ◽  
Yoshio MORIOKA ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Genetic Polymorphism ◽  
Immunoglobulin A ◽  
Immunoglobulin A Nephropathy

Immunoglobulin A nephropathy

2018 ◽  
Author(s):  
Kar Neng Lai ◽  
Sydney C. W. Tang
Keyword(s):  
Blood Pressure ◽  
Immunoglobulin A ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Convincing Evidence ◽  
High Dose ◽  
Immunoglobulin A Nephropathy ◽  
Recurrent Tonsillitis ◽  
Converting Enzyme Inhibitors ◽  
End Stage

Immunoglobulin A nephropathy is characteristically slowly evolving, and studies from autopsies and kidney donors show that deposition of immunoglobulin A is quite common and not necessarily associated with overt disease. However, series of biopsy-diagnosed patients that extend to 20 or 30 years report rates of end-stage renal failure of up to 40–50%. A very approximate overall rate of end-stage renal disease of 1% per year has been suggested. Proteinuria, glomerular filtration rate (GFR), and possibly some features on renal biopsies enable risk stratification, but all patients need long-term monitoring. Treatment is based on the use of angiotensin converting-enzyme inhibitors for patients with proteinuria, and blood pressure control, and of course during most of the previous long-term studies patients would not have been treated with these agents or to modern blood pressure standards. For patients who show loss of GFR despite this, or other markers of high risk, the best evidence is for treatment with high-dose corticosteroids over a limited period of months. There is little convincing evidence for additional benefit from cytotoxic or other immunomodulatory agents, except possibly in the most aggressive disease, when there is weak evidence for cyclophosphamide. Some studies claim benefit from tonsillectomy, but this is not clear, and most nephrologists only recommend this for patients with recurrent tonsillitis.

Sign in / Sign up

Export Citation Format

Share Document